Trevigen introduces a highly sensitive, quantitative, and validated assay to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anti-cancer drug screening. These assays provide the opportunity to prospectively identify patients likely to respond in clinical trials. This high throughput, chemiluminescent assay kit has been validated on human peripheral blood lymphocytes Trevigen, Inc., 800-873-8443, www.trevigen.com